Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03437044 · ClinicalTrials.gov registry record · Phase 4
Low Maintenance Dose Ticagrelor Versus Clopidogrel in Diabetes Patients Undergoing PCI
A Phase 4 study of Diabetes Mellitus, Type 2 and Coronary Artery Disease, sponsored by University of Florida.
- Completed
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT03437044 is a Phase 4 study of Diabetes Mellitus, Type 2 and Coronary Artery Disease that has completed, run by University of Florida. The registered enrollment target is 40 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03437044, a Phase 4 study of Diabetes Mellitus, Type 2 and Coronary Artery Disease, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
To date there is very little PD and pharmacokinetic (PK) data on the ticagrelor 60 mg bid dosing regimen. In particular, there is no prospective PK/PD study on this dosing regimen in patients with DM who are known to have impaired response to clopidogrel therapy. Since DM patients frequently require elective PCI due to chronic progression of CAD (and not solely because of an acute thrombotic complication), and clopidogrel remains the guideline recommended P2Y12 inhibiting therapy for these patients, understanding the PD effects of the ticagrelor 60 mg bid regimen in this setting is an unmet clinical need. This is also in light of the ongoing THEMIS trial which is specifically evaluating the impact of the ticagrelor 60 mg bid dosing regimen in type 2 DM patients without a prior major CV event.
Conditions Studied
Interventions
- DRUG Clopidogrel
- DRUG Ticagrelor
Study Locations (1)
Florida
- University of Florida - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2018-03-14 |
| Est. Completion | 2020-06-27 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03437044
The ClinicalTrials.gov registry entry for NCT03437044 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (99% lower). The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which Clopidogrel is the first listed.
NCT03437044 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT03437044 about?
NCT03437044 is a clinical study titled "Low Maintenance Dose Ticagrelor Versus Clopidogrel in Diabetes Patients Undergoing PCI". To date there is very little PD and pharmacokinetic (PK) data on the ticagrelor 60 mg bid dosing regimen. In particular, there is no prospective PK/PD study on this dosing regimen in patients with DM who are known to have impaired response to clopidogrel therapy. Since DM patients frequently require...
What is the current status of trial NCT03437044?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2018-03-14. Estimated completion is 2020-06-27.
What conditions does trial NCT03437044 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, Coronary Artery Disease.
What interventions are being tested in trial NCT03437044?
The interventions under investigation include: Clopidogrel (DRUG), Ticagrelor (DRUG).
Who is sponsoring clinical trial NCT03437044?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03437044 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes
RECRUITING · Phase 4
-
Knee Osteoarthritis Treatment With Zilretta vs. Kenalog in the Context of Type II Diabetes
RECRUITING · Phase 4
-
Effect of Continuing Versus Holding Metformin During Hospitalizations.
RECRUITING · Phase 4
-
Surgical or Medical Treatment
ACTIVE NOT RECRUITING · Phase 4
-
Afrezza® Dosing Optimization Study
COMPLETED · Phase 4
-
Effect of Thiazolidinedione Treatment Vascular Risk Markers
COMPLETED · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.